These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31235865)

  • 1. Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
    Berndsen RH; Castrogiovanni C; Weiss A; Rausch M; Dallinga MG; Miljkovic-Licina M; Klaassen I; Meraldi P; van Beijnum JR; Nowak-Sliwinska P
    Br J Cancer; 2019 Jul; 121(2):139-149. PubMed ID: 31235865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
    Mathias TJ; Natarajan K; Shukla S; Doshi KA; Singh ZN; Ambudkar SV; Baer MR
    Invest New Drugs; 2015 Apr; 33(2):300-9. PubMed ID: 25597754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of crenolanib, a nonselective inhibitor of PDGFR, in a mouse model of transient middle cerebral artery occlusion.
    Wang J; Fu X; Zhang D; Yu L; Lu Z; Gao Y; Liu X; Man J; Li S; Li N; Wang M; Liu X; Chen X; Zang W; Yang Q; Wang J
    Neuroscience; 2017 Nov; 364():202-211. PubMed ID: 28943249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crenolanib is a selective type I pan-FLT3 inhibitor.
    Smith CC; Lasater EA; Lin KC; Wang Q; McCreery MQ; Stewart WK; Damon LE; Perl AE; Jeschke GR; Sugita M; Carroll M; Kogan SC; Kuriyan J; Shah NP
    Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5319-24. PubMed ID: 24623852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo.
    Wang P; Song L; Ge H; Jin P; Jiang Y; Hu W; Geng N
    Onco Targets Ther; 2014; 7():1761-8. PubMed ID: 25328409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
    Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
    Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
    Mahboobi S; Uecker A; Sellmer A; Cénac C; Höcher H; Pongratz H; Eichhorn E; Hufsky H; Trümpler A; Sicker M; Heidel F; Fischer T; Stocking C; Elz S; Böhmer FD; Dove S
    J Med Chem; 2006 Jun; 49(11):3101-15. PubMed ID: 16722630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crenolanib-Derived Probes Suitable for Cell- and Tissue-Based Protein Profiling and Single-Cell Imaging.
    Chang Y; Zhu D; Guo H; Yin X; Ding K; Li Z
    Chembiochem; 2019 Jul; 20(14):1783-1788. PubMed ID: 30942519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the inhibitor discrimination by FLT3 F691L.
    Verma S; Singh A; Kumari A; Pandey B; Jamal S; Goyal S; Sinha S; Grover A
    Chem Biol Drug Des; 2018 May; 91(5):1056-1064. PubMed ID: 29336115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenite suppresses angiogenesis of vascular endothelial cells mediated by Platelet Derived Growth Factor Receptor-beta.
    Wang X; Mou Y; Yue Z; Zhang H; Su X; Wang Y; Li R; Sun X
    Environ Toxicol Pharmacol; 2016 Sep; 46():168-173. PubMed ID: 27475902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.
    Makino K; Makino T; Stawski L; Mantero JC; Lafyatis R; Simms R; Trojanowska M
    J Invest Dermatol; 2017 Aug; 137(8):1671-1681. PubMed ID: 28433542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR.
    Kamiyama H; Kakeya H; Usui T; Nishikawa K; Shoji M; Hayashi Y; Osada H
    Oncol Res; 2008; 17(1):11-21. PubMed ID: 18488711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
    Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.